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In humans, herpes simplex virus (HSV) estab-
lishes latency in sensory nerve ganglia from
where it periodically reactivates, whereas in
murine models, the virus efficiently establishes
latency but rarely reactivates. HSV inhibits
MHC class I antigen presentation to CD8 T cells
efficiently in humans but poorly in mice, and
whether this is a crucial determinant of HSV’s
ability to reactivate in humans remains uncer-
tain. To test this, we generated a panel of
recombinant HSVs that inhibit presentation by
murine MHC class I mimicking the effect in
humans. Antigen-specific CD8 T cells prevent
the in vivo reactivation of wild-type HSV.
Despite their presence in the ganglia of latently
infected mice, CD8 T cells do not prevent the
reactivation of recombinant HSVs that inhibit
murineMHC class I inmice. These findings sug-
gest that efficient inhibition of MHC class I by
HSV is a key factor in its ability to reactivate in
humans.
INTRODUCTION
Herpes simplex virus (HSV) is one of the most common
human pathogens, infecting 50%–70% of the world pop-
ulation (Smith and Robinson, 2002). While HSV infection
can cause serious or fatal disease in neonates and the
immunocompromised, and ocular infection may lead to
corneal scaring and blindness in normal hosts (Liesegang,
2001; Looker and Garnett, 2005; Whitley and Roizman,
2001), it typically manifests as lesions at mucosal sur-
faces. These recurrent lesions occurring periodically
over the lifetime of an infected individual reflect reactiva-
tion of latent HSV infection, which is established in the
sensory nerve ganglia at the time of primary infection.
This life-long infection results in limited morbidity but facil-
itates transmission to new hosts and thereby helps to172 Cell Host & Microbe 2, 172–180, September 2007 ª2007 Esustain the high prevalence of HSV infection in the human
population.
The traditional model of HSV latency posits that viral
protein production is halted, and the virus is maintained
in a quiescent state in which only an untranslated
mRNA, LAT, is produced. However careful analysis of
latently infected murine ganglia has revealed infrequent,
but readily detectable viral protein production, indicating
that latency is leakier than previously thought (Feldman
et al., 2002). These proteins may be processed and pre-
sented by MHC class I to virus-specific CD8 T cells, allow-
ing detection and repression of overt viral reactivation
(Khanna et al., 2004a). Consistent with this notion, CD8
T cells have been found to colocalize with latently infected
cells in the trigeminal ganglia of both humans and mice
(Hufner et al., 2006; Khanna et al., 2003; Pereira and Sim-
mons, 1999; Theil et al., 2003). In humans, a substantial
number of these cells are HSV specific and bear markers
associated with an effector or effector memory phenotype
(Verjans et al., 2007); many of these cells express the ac-
tivation markers CD69 and granzyme B and are in close
proximity to neurons expressing HSV LAT, suggesting on-
going exposure to viral antigens. In mice, these T cells are
predominantly HSV specific, often have TCRs clustered at
points of contact with adjacent neurons, and express
CD69 and granzyme B, indicating recent antigen expo-
sure (Khanna et al., 2003; van Lint et al., 2005). These
HSV-specific CD8 T cells prevent reactivation in vitro in
a partially IFN-g-dependent manner (Khanna et al.,
2003; Liu et al., 2000, 2001). In vivo reactivation after
hyperthermic stress or UV exposure is increased in IFN-g-
and IFN-gR-deficient mice (Cantin et al., 1999; Minami
et al., 2002). These findings indicate that antigen presen-
tation to CD8 T cells is ongoing during latency, and that
these HSV-specific CD8 T cells may limit reactivation.
Accordingly, eliciting a robust CD8 T cell response is the
objective of several potential therapeutic HSV vaccines
(Koelle, 2006).
To counter the CD8 T cell response, HSV encodes
multiple immune evasion strategies, including inhibition
of antigen presentation by MHC class I (Tortorella et al.,
2000). HSV ICP47 binds to the transporter associatedlsevier Inc.
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peptides from being loaded onto nascent MHC class I
heavy chains (Hill et al., 1995). An ICP47-deletion virus
was shown to be less neurovirulent, and this decrease
was due to CD8 T cells, as depletion of these cells re-
stored neurovirulence (Goldsmith et al., 1998). While
ICP47 effectively blocks MHC class I antigen presentation
on infected human cells, inhibition of presentation by mu-
rine cells is only marginally reduced, due to the low affinity
of ICP47 for murine TAP1/2 (Tomazin et al., 1996, 1998;
Jugovic et al., 1998; Ahn et al., 1996). These findings sug-
gest that the effects of ICP47 in vivo are likely to be much
greater in humans than in mice.
To mimic in mice the effects of ICP47 in humans, we
previously generated recombinant herpes simplex viruses
(rHSVs) that also express either human cytomegalovirus
(HCMV) US11 (designated 27US11) or murine CMV
m152 (designated 27m152) in addition to gfp, and a control
virus (designated 27gfp) that expresses gfp but not an
MHC class I inhibitor (Orr et al., 2005). Both 27US11 and
27m152 reduced surface expression of murine MHC class
I, rendering infected cells less susceptible to recognition
and killing by CD8 T cells, leading to a loss of CD8 T
cell-mediated control and increased virulence during
acute infection (Orr et al., 2005). We now show that
HSV-mediated inhibition of MHC class I antigen presenta-
tion during latency abrogated CD8 T cell control of viral
reactivation using both in vitro and in vivo models of HSV
reactivation. Further, in the case of m152-mediated inhibi-
tion, this immune evasion strategy also reduced the fre-
quency and activation of HSV-specific CD8 T cells in the
latently infected trigeminal ganglia. These data demon-
strate that latent HSV is under immune surveillance, and
that the virus is able to counteract this surveillance and
to reactivate in the presence of HSV-specific CD8 T cells.
RESULTS
Clearance of Primary Infection and Establishment
of Latency
We previously demonstrated that viral inhibition of MHC
class I resulted in increased viral titers during primary in-
fection of mice inoculated in the footpad (Orr et al.,
2005). To determine whether viral inhibition of MHC class
I affected the course of primary ocular infection, we ana-
lyzed viral shedding by sequentially swabbing both eyes
of infected mice over a 10 day period and measured viral
titers in homogenates of eyes and trigeminal ganglia from
additional mice sacrificed at intervals over the first 14 days
of infection. The amounts of virus shed from the eyes were
similar for 27gfp, 27US11, and 27m152 through day 7, and
shedding ceased by day 10 postinfection (Figure 1A). Viral
abundance in eye homogenates followed a similar pattern,
with the greatest amounts at day one and clearance by
day 14 (Figure 1B). Whereas peak titers in the trigeminal
ganglia were observed on day 3, virus was also cleared
from this site by day 14 (Figure 1C). 27m152 demonstrated
a replication advantage over 27gfp in both tissues by day 3
postinfection, while 27US11 demonstrated a similar ad-Cell Host &vantage in the trigeminal ganglia but not in eye homoge-
nates. Nonetheless, by 14 days postinfection these vi-
ruses were uniformly cleared, irrespective of their ability
to inhibit MHC class I.
Previous reports have demonstrated that the amount of
latent virus correlates with the amount of virus in the initial
inoculum (Lekstrom-Himes et al., 1998; Maggioncalda
et al., 1996; Sawtell, 1998). Since 27US11 and 27m152
both replicated to higher titers than 27gfp in the trigeminal
ganglia by day 3 and maintained this advantage until all vi-
ruses were cleared, we hypothesized that viral inhibition of
MHC class I would result in an increased amount of latent
virus. Surprisingly, at 2 weeks postinfection the numbers
of latent viral copies in the trigeminal ganglia were slightly
reduced in 27US11 or 27m152-infected mice, as
Figure 1. Viral Inhibition of MHC Class I Does Not Prolong or
Prevent the Clearance of Primary Infection
Female C57Bl/6 mice were infected with 2 3 105 pfu/eye of the indi-
cated viruses. (A) Eight mice/virus were serially swabbed for viral
shedding from both eyes on the indicated days. Alternatively, on the
indicated days four mice/virus were euthanized, and the eyes (B) and
trigeminal ganglia (C) were harvested. Viral titers were determined
by plaque formation on Vero cells. Statistically significant increases
in viral titer compared to 27gfp on the same day are indicated (*p <
0.05 and **p < 0.01). Error bars = one SEM; n.d., not detected.Microbe 2, 172–180, September 2007 ª2007 Elsevier Inc. 173
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ferences were not statistically significant (Figure 2). Thus,
viral inhibition of MHC class I favored replication during
acute infection but did not prevent viral clearance or in-
crease the amount of latent virus.
CD8 T Cell Response during Latency
As previously reported with wild-type HSV (Khanna et al.,
2003), 2 weeks after primary infection with 27gfp HSV-
specific CD8 T cells were readily found within latently
infected trigeminal ganglia as detected by staining with
H-2Kb dimer loaded with the immunodominant HSV pep-
tide gB498-505 (Wallace et al., 1999) (Figure 3A). Whereas
mice latently infected with 27US11 and 27gfp had a similar
frequency of HSV-specific CD8 T cells in the trigeminal
ganglia at this time point, there were significantly fewer
HSV-specific cells in ganglia latently infected with
27m152 (Figure 3A). The frequencies of HSV-specific
CD8 T cells did not change from 2 (Figure 3A) to 5 (Fig-
ure 3B) weeks postinfection, indicating that this number
is set by 2 weeks postinfection. A similar decrease in the
frequency of HSV-specific CD8 T cells in 27m152-infected
mice was observed by intracellular staining for IFN-g after
restimulation with the gB peptide; this finding corrobo-
rates the results obtained by H-2Kb-gB dimer staining
and indicates that the fraction of HSV gB-specific CD8 T
cells capable of producing IFN-g directly ex vivo was
similar for the three viruses (Figure 3C). By 5 weeks post-
infection, the majority of the gB-specific CD8 T cells in the
trigeminal ganglia of 27gfp-infected mice expressed gran-
zyme B. In 27m152-infected mice, we observed a subtle
though reproducible and statistically significant (p <
0.001) reduction in the fraction of gB-specific CD8 T cells
expressing granzyme B ex vivo, as compared to 27gfp-in-
fected mice, suggesting that fewer of these antigen-spe-
cific CD8 T cells had recently encountered cognate pep-
tide-MHC (van Lint et al., 2005) (Figure 3D). Together,
these data indicate that inhibition of MHC class I by
27m152, but not by 27US11, reduced the number and
Figure 2. The Amount of Latent Viral DNA IsUnaltered by Viral
Inhibition of MHC Class I
The relative quantity of viral DNA in the trigeminal ganglia of latently in-
fected mice 2 weeks postinfection was determined by real-time PCR
for viral genomic DNA and normalized to the number of copies of the
murine adipsin gene in each sample. Sixteen to twenty-four ganglia/
virus were analyzed. Error bars = one SEM. Data are pooled from
two experiments with similar results. There were no statistically signif-
icant differences among the groups.174 Cell Host & Microbe 2, 172–180, September 2007 ª2007 Eldegree of activation of gB-specific CD8 T cells within the
latently infected ganglia. The greater impact of m152 com-
pared to US11 on HSV-specific CD8 T cells may be due to
the more efficient blockade by m152 of antigen presenta-
tion by cells expressing H-2b (Orr et al., 2005).
In Vitro Reactivation
HSV-specific CD8 T cells can prevent in vitro reactivation
of wild-type HSV from explanted latently infected ganglia
(Khanna et al., 2003; Liu et al., 2000). In good agreement
with these reports, we found that HSV-specific CD8 T cells
efficiently prevented reactivation of 27gfp from cultures of
dissociated, latently infected ganglia that were explanted
14 days postinfection (Figure 4A). Reactivation was pre-
vented by CD8 T cells, as addition of blocking CD8 anti-
body resulted in 100% reactivation by all three viruses
(Figure 4B). However, 27m152 and 27US11 reactivated
much more readily from latently infected ganglia in the
presence of HSV-specific CD8 T cells (Figure 4A). Thus,
by limiting antigen presentation by MHC class I,
27m152, and to a lesser extent, 27US11 were able to reac-
tivate more efficiently in the presence of virus-specific
CD8 T cells.
In Vivo Reactivation
Although spontaneous reactivation is rare in mice, reacti-
vation can be induced by hyperthermia or exposure to UV
light (Laycock et al., 1991; Sawtell and Thompson, 1992).
Since the latter is a known cause of HSV reactivation in hu-
mans (Rooney et al., 1991), we examined the impact of
MHC class I inhibition on reactivation in vivo as deter-
mined by the recovery of lytic virus from the eyes and tri-
geminal ganglia following exposure of latently infected
mice to UV irradiation. These rHSVs were made in the
KOS strain of HSV-1 that reactivates less frequently than
many other HSV strains (Sawtell et al., 1998), allowing us
to determine more readily whether viral inhibition of
MHC class I increases the reactivation frequency in vivo.
The frequency of reactivation 5 weeks after infection
was significantly higher for mice infected with 27US11 or
27m152 compared to mice infected with 27gfp (Figure 5B).
In a portion of the mice, we quantified the amount of virus
in the homogenates from the trigeminal ganglia and eyes
separately (Figure 5A). Although the absolute numbers of
plaque-forming units recovered were low, in the few mice
in which 27gfp reactivated, virus was recovered only from
the trigeminal ganglia. Conversely, a subset of the animals
infected with 27US11 and 27m152 had virus recovered
from their eyes in addition to their trigeminal ganglia. In
no case was virus recovered from eye but not trigeminal
ganglia homogenates. Consistent with the low levels of
virus detected in these tissue homogenates, we rarely
detected viral shedding in the swabbed eyes with any of
these viruses (data not shown). The increased rate of reac-
tivation in mice infected with 27US11 and 27m152 was not
simply due to decreased numbers of HSV-specific CD8 T
cells, as 27US11 reactivated more frequently than 27gfp
even though the number and activation status of thesesevier Inc.
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Ganglia
HSV gB-specific CD8 T cells in latently infected trigeminal ganglia at 14–16 (A) or 32–46 (B and C) days postinfection were identified by binding of
H-2Kb DimerX loaded with HSV gB498-505 peptide (A and B) or by gB peptide-induced IFN-g production (C). (D) The activation status of HSV gB-spe-
cific CD8 T cells was determined as the percentage of H-2Kb-gB DimerX-positive CD8 T cells that contained intracellular granzyme B directly ex vivo.
The cells shown in the plots are gated on total cells (A–C) or CD8 T cells (D) in the trigeminal ganglia. The bar graphs indicate the mean percentage ±
SEM of CD8 T cells that are specific for HSV gB (A–C) or of HSV gB-specific CD8 T cells that express granzyme B ex vivo (D). Data are pooled from
three (A), five (B), four (C), and two (D) experiments with similar results; in each experiment, eight to ten ganglia/virus were analyzed. The difference
between mice infected with 27m152 compared to 27gfp in each panel was statistically significant (p < 0.0001). Error bars = one SEM.cells in the trigeminal ganglia of 27US11-infected mice
were similar to 27gfp-infected mice (Figure 3).
To test directly whether the increased rate of reactiva-
tion of 27US11 and 27m152 was due to the ability of these
viruses, but not 27gfp, to efficiently evade control by CD8
T cells, we depleted these cells in latently infected mice
prior to UV exposure. CD8 depletion, but not treatment
with an IgG2b isotype control antibody, led to a markedly
increased frequency of 27gfp reactivation that was similar
to the frequency of reactivation of 27US11 and 27m152
(Figure 6). Conversely, depletion of CD8 T cells had little
impact on the already high reactivation frequency of
27US11 and 27m152. These results indicate that inhibition
of MHC class I antigen presentation by 27US11 and
27m152 increased the probability of reactivation by limit-
ing the efficacy of CD8 T cells in preventing reactivation.
DISCUSSION
Previous studies have shown that HSV-specific CD8 T
cells are in close association with latently infected murine
ganglia, and that these cells prevent HSV reactivation in
vitro (Khanna et al., 2003; Liu et al., 2000). However, a ca-Cell Host & Mveat regarding the applicability of these studies to HSV
infection in humans is the ability of HSV to efficiently inhibit
human but not murine MHC class I antigen presentation to
CD8 T cells (Ahn et al., 1996; Jugovic et al., 1998; Tomazin
et al., 1996, 1998). Using rHSVs that express either HCMV
US11 or MCMV m152, both of which inhibit murine MHC
class I antigen presentation (Orr et al., 2005), we found
that CD8 T cell control of reactivation is muted by this im-
mune evasion strategy. Although viral inhibition of MHC
class I increased the viral burden during primary infection,
it neither prevented the clearance of primary infection nor
increased the number of viral genomes in the latently in-
fected trigeminal ganglia. Although the establishment of
latency was not altered, the numbers of HSV-specific
CD8 T cells residing in the latently infected ganglia were
diminished in mice infected with 27m152. This decrease
in cell numbers coincided with a decreased activation
state of these cells, suggesting that ongoing antigen pre-
sentation is required to maintain HSV-specific CD8 T cells
in latently infected ganglia. Independent of the alteration
of CD8 T cell numbers, both 27US11 and 27m152 reacti-
vated efficiently in the presence of HSV-specific CD8 T
cells in vitro, whereas the control virus, 27gfp, did not.icrobe 2, 172–180, September 2007 ª2007 Elsevier Inc. 175
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vate in the Presence of HSV-Specific
CD8 T Cells
Reactivation of rHSVs in vitro from explanted,
latently infected trigeminal ganglia in the pres-
ence of effector HSV-specific CD8 T cells plus
IL-2 and either IgG2b isotype control (A) or a-
CD8 monoclonal antibody (B) (n = 8 trigeminal
ganglia/group).
(A) The increased frequencies of reactivation
for 27US11 (p = 0.01) and 27m152 (p =
0.0017) compared to 27gfp were statistically
significant.
(B) The results for 27gfp and 27US11 data were
identical, and thus the symbols for 27US11 are
not apparent in the figure.Using an UV-induced model of reactivation, we found that
viral inhibition of MHC class I enhanced the rate of viral
reactivation in vivo. This enhancement reflected the ability
of 27US11 and 27m152 to evade CD8 T cell-mediated
control, as depletion of CD8 T cells resulted in efficient re-
activation by 27gfp and comparable rates of reactivation
by all three viruses. These results demonstrate that HSV
reactivation is under immunological surveillance by CD8
T cells, but that CD8 T cell-mediated control is subverted
by efficient viral inhibition of MHC class I.176 Cell Host & Microbe 2, 172–180, September 2007 ª2007 EAlthough 27US11 and 27m152 both demonstrated an
increased frequency of reactivation in vitro and in vivo,
the effects of m152 were consistently stronger than US11.
Additionally, expression of 27m152, but not 27US11, re-
duced the frequency and activation status of HSV-specific
CD8 T cells within the latently infected trigeminal ganglia.
This difference may be due to a greater inhibition of MHC
class I in cells infected with 27m152 than in cells infected
with 27US11, as we previously reported (Orr et al., 2005).
However, we cannot exclude the possibility that additionalFigure 5. Viral Inhibition of MHC Class I
Promotes Reactivation In Vivo
In vivo reactivation from the trigeminal ganglia
and eyes of latently infected mice following
UV exposure 5 weeks postinfection.
(A) The numbers of recovered pfus from the tri-
geminal ganglia and eyes are shown. In some
mice virus was recovered from both sites,
and in others virus was recovered only in the
trigeminal ganglia. Virus was never recovered
from the eyes but not the trigeminal ganglia.
Data represent 18 to 19 mice/virus and were
pooled from two experiments with similar
results.
(B) The overall frequency of reactivation in the trigeminal ganglia for each virus and treatment group is shown. Data are from 27 to 31 mice/virus pooled
from three experiments, including the two experiments shown in (A) and a third experiment in which reactivation was determined on a combined
homogenate of the ganglia and eyes. Statistically significant increases versus 27gfp are indicated (*p < 0.05 and **p < 0.01).lsevier Inc.
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Abrogates CD8 T Cell Prevention of
HSV Reactivation
In vivo reactivation of rHSV following UV expo-
sure in eight to ten latently infected mice
treated with a-CD8 or IgG2b isotype control
Ab.
(A) The numbers of recovered pfus from both
the trigeminal ganglia and eyes are shown. In
some mice virus was recovered from both
sites, and in others virus was recovered only
from the trigeminal ganglia. Virus was never re-
covered from the eyes but not the trigeminal
ganglia.
(B) The overall frequency of reactivation in the
trigeminal ganglia for each virus and treatment
group is indicated. The results shown are from
one of two experiments performed with similar
results in both.functions of m152, including inhibition of NKG2D ligand
expression on the surface of infected cells, may contribute
to the greater effects observed with this virus (Ehrlich
et al., 2005; Krmpotic et al., 2002; Lodoen et al., 2003).
During primary infection, both 27US11 and 27m152 repli-
cated to higher titers in the trigeminal ganglia, but only
27m152 replicated to higher titers in the periphery. This
difference likely results, at least in part, from the ability
of m152 to inhibit recognition by CD8 T cells even in the
periphery, where MHC class I expression is higher,
whereas US11 was only able to do so in the ganglia, where
MHC class I expression is low compared to the periphery.
Several studies have demonstrated that the rate of re-
activation correlates with the numbers of latently infected
neurons in the ganglia, suggesting that these numbers
may be the prime determinant of reactivation (Lekstrom-
Himes et al., 1998; Maggioncalda et al., 1996; Sawtell,
1998). We found that the amount of latent virus was not
affected by viral inhibition of MHC class I, yet the rate of
reactivation was significantly higher for both 27US11
and 27m152. These findings suggest that the degree to
which the virus evades local CD8 T cell-mediated control
is a second determinant of the frequency of reactivation,
independent of the amount of latent virus.
The canonical view of latency holds that production of
viral proteins in the ganglia is abrogated, removing the
source of antigenic peptides that are presented by MHC
class I to CD8 T cells. However, careful analysis of latently
infected murine trigeminal ganglia reveals low but readily
detectable amounts of viral proteins, indicating that latency
is less silent than previously thought (Feldman et al., 2002).
These data suggest a model in which a subset of viral pro-
teins is transcribed during latency at relatively low levels.
These proteins are in turn processed and presented by
MHC class I to CD8 T cells residing in the ganglia (Khanna
et al., 2004b). If these cells mount a vigorous, partially IFN-
g-mediated response, viral reactivation is aborted (Dec-
man et al., 2005). Conversely, if this response is muted orCell Host & Mabsent, such as in the absence of IFN-g or its receptor,
then viral reactivation proceeds (Cantin et al., 1999).
It was previously thought that uninfected neurons do not
express MHC class I, and that MHC class I expression
was induced only transiently in response to acute infection
with HSV, during which time CD8 T cells helped to control
the infection (Pereira and Simmons, 1999; Pereira et al.,
1994). However, it has recently been appreciated using
more sensitive methods that neurons do express MHC
class I at low levels, and that expression is regulated in
part by neuronal activity (Goddard et al., 2007). These
findings, along with the observations that viral antigens
distinct from LAT are expressed at low levels during la-
tency (Feldman et al., 2002), that CD8 T cells colocalize
with latently infected cells in the trigeminal ganglia of both
humans and mice (Hufner et al., 2006; Khanna et al., 2003;
Theil et al., 2003), and that a substantial number of these
cells are HSV specific and bear markers indicating recent
antigen exposure (Khanna et al., 2003; van Lint et al.,
2005; Verjans et al., 2007), suggest that latently infected
ganglia are under active immunological surveillance by
CD8 T cells. Despite the presence of HSV-specific CD8
T cells, subclinical reactivation is a common occurrence
in humans, suggesting that these cells are inefficient in
controlling HSV reactivation from latently infected human
sensory neurons where MHC class I expression is low and
thus the impact of ICP47 is much more pronounced
(Crespi et al., 2007). Our data support this conclusion, as
inhibition of murine MHC class I by 27US11 or 27m152
dramatically increased the rate of reactivation within the
trigeminal ganglia, whereas the recovery of reactivated vi-
rus from the eye was less frequent. Our findings are also
consistent with the recent finding that the primary site of
immunological control of HSV-2 reactivation in humans
is in the periphery, where HSV-specific CD8 T cells local-
ize to recurrent HSV skin lesions and where infiltration by
these cells correlates with viral clearance, rather than in
the ganglia (Zhu et al., 2007).icrobe 2, 172–180, September 2007 ª2007 Elsevier Inc. 177
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model of HSV latency and reactivation (Cantin et al.,
1995; Hufner et al., 2006; Khanna et al., 2004a). CD8 T
cells can act as sentinels to terminate nascent reactivation
in mice, but efficient inhibition of MHC class I allows HSV
to evade CD8 T cell control and shift the balance in favor of
reactivation. These findings suggest that efficient inhibi-
tion of MHC class I by HSV is an important determinant
of this virus’s ability to reactivate and thereby to be trans-
mitted to others over the lifetime of an infected individual.
These findings also have implications for the development
of a therapeutic vaccine for HSV, as induction of virus-
specific CD8 T cells may not alone be sufficient to prevent
reactivation or clear latent infection in humans, although
they may limit the frequency and/or duration of recurrent
lesions.
EXPERIMENTAL PROCEDURES
Viruses
Generation of the recombinant HSVs 27gfp, 27US11, and 27m152 was
described previously (Orr et al., 2005). Briefly, targeting constructs
containing the genes encoding HCMV US11 or MCMV m152 under
the HCMV IE promoter, eGFP under the EF promoter, and GPT under
the PGK promoter were flanked with DNA homologous to HSV UL26
and UL27. Targeting constructs were linearized and electroporated
into Vero cells. Cells were then infected with KOS strain HSV-1. Re-
combinant viruses were isolated based on expression of gfp and pla-
que purified. A control virus designated 27gfp containing only gfp and
gpt was generated in a similar manner.
Mice and Infection
Six- to eight-week-old female C57Bl/6 were purchased from Jackson
Labs (Bar Harbor, ME) and maintained in the University of Washington
SPF facility. Prior to infection, mice were anesthetized with a mixture of
ketamine and xylazine. Corneas were abraded with a 30G needle
passed six times across the cornea. Mice were inoculated in both
eyes with 23 105 pfu of the indicated virus in 3 ml. Mice were monitored
daily for development of ataxia. Affected mice were euthanized. All
studies were approved by the University of Washington Institutional
Animal Care and Use Committee.
Quantification of Lytic Virus
Mice were sacrificed by administration of Beuthanasia-D solution
(Schering-Plough Union, NJ). Trigeminal ganglia and eyes were re-
moved and snap frozen on dry ice. Frozen tissue was homogenized
and plated on Vero cells. To quantify viral shedding, mice were
swabbed in both eyes. Swabs were soaked in 0.5 ml media, and the
media were transferred directly to Vero cells. Plaques were visualized
72–96 hr later by addition of crystal violet dye.
Detection of Latent Virus
Total DNA was isolated from latently infected trigeminal ganglia using
a DNeasy Tissue kit (QIAGEN, Valencia, CA) following the Total DNA
from Animal Tissues protocol. Relative abundances of viral and murine
DNA were determined by real-time PCR for HSV ICP47 or murine adip-
sin, respectively, using SYBR Green (Stratagene, Cedar Creek, TX).
The following primers were used: ICP47 forward, CACGTTTGCAGCG
CACATGC; ICP47 reverse, CTTGCGCACCTGGTGATGTT; murine
adipsin forward, AAGTGATCGCTACAAGTTGT; murine adipsin re-
verse, ACTTGCACGGAAGCCATGTA.
Quantification of CD8 T Cell Response
On the indicated day, mice were sacrificed as above and exsangui-
nated. Trigeminal ganglia were harvested and dissociated by treat-178 Cell Host & Microbe 2, 172–180, September 2007 ª2007 Elment with 3 mg/ml collagenase type I (Sigma-Aldrich, St Louis, MO)
for 90 min at 37C. Ganglia were then triturated into single-cell suspen-
sions. Cells were stimulated with 5 mM of the immunodominant HSV
peptide glycoprotein B498–505 (gB498–505) (United Biochemical Re-
search, Seattle, Washington) for 5 hr in the presence of monensin, fol-
lowed by surface staining with a-CD8 and a-CD45.2, permeabilized
using the Intracellular Staining Kit from BD Biosciences, and stained
for intracellular IFN-g. Unstimulated lymphocytes were used as a neg-
ative control. Antigen-specific IFN-g production = percentage CD8+
IFN-g+ stimulated  unstimulated. Alternatively, freshly isolated cells
were stained with a-CD8, a-CD45.2, and H-2Kb DimerX loaded with
either HSV gB peptide or an irrelevant peptide according to the man-
ufacturer’s specifications and stained intracellularly for granzyme B.
DimerX, and antibodies were purchased from BD Biosciences Phar-
Mingen.
In Vitro Reactivation
Latently infected trigeminal ganglia were harvested 14 days postinfec-
tion and treated as for CD8 T cell quantification. Single-cell suspen-
sions were cultured in the presence of 100 U/ml IL-2, 2.5 3 106 total
activated lymphocytes isolated from the draining lymph nodes of
mice infected 6 days prior, and 150 mg of either a-CD8 (clone 2.43)
or IgG2b isotype control. Cultures were assayed for reactivation daily
by transferring 150 ml to Vero cells, which were monitored for plaque
formation as described above. Fresh medium containing IL-2 was
added to keep culture volumes and content constant.
In Vivo Reactivation
Five weeks after acute infection, latently infected mice were exposed
to 945 mJ/cm2 UV-B light using a handheld UV transilluminator (Ul-
tra-Violet Products model UVM-57, Upland, CA) with a peak emission
at 302 nm. Mice were covered such that only the eyes received UV ex-
posure. Three days postexposure, mice were sacrificed and assayed
for lytic virus in the eyes and trigeminal ganglia as described for quan-
tification of lytic virus. Animals were scored as positive for reactivation
if lytic virus was recovered from the trigeminal ganglia. CD8 T cells
were depleted from some mice by i.p. injection of 200 mg of a-CD8
(clone 2.43) or IgG2b isotype control on days 3 and 2 relative to
UV treatment.
Statistical Analysis
Statistical differences in viral titers and frequency of HSV-specific CD8
T cells were determined by two-tailed unpaired Student’s t test. Statis-
tical significance for in vitro and in vivo reactivation were determined
by Chi square test. Statistical differences in the titers of reactivated
virus were determined by unpaired Mann-Whitney test. Statistics were
determined with Prism software (GraphPad Software, Inc).
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